Biofrontera Inc. (BFRI): Nasdaq/NYSE listing notice — Biofrontera receives Nasdaq non-compliance notice for bid price below $1.00 per share

Biofrontera Inc.

Nasdaq notified Biofrontera on Feb 24, 2023, that common stock bid price closed below $1.00 for 30 consecutive business days.
Company has 180 days, until Aug 23, 2023, to regain compliance by achieving $1.00 closing bid for 10 consecutive days.
If not cured, Biofrontera may qualify for a second 180-day period by meeting other listing standards and effecting a reverse stock split.
No immediate impact on trading; delisting possible if compliance not regained.
Company intends to monitor bid price and consider available options; no assurance of regaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Biofrontera Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 24, 2023, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 30 consecutive business days. The notice has no present impact on the listing or trading of the Company’s securities on The Nasdaq Capital Market. Un

View on SEC.gov

Browse all listing & compliance notices →

Biofrontera Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-006497

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.